~~<i id='91C59CC850'><strike id='91C59CC850'><tt id='91C59CC850'><pre id='91C59CC850'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：focus 2025-09-27 19:01:54 - browse：5

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

entertainment

knowledge

explore

focus

leisure time

MollyFergusonforSTATZariawasjust9yearsoldwhenanursepractitionerdeliverednewsthatrockedherworld:Theyo

WSS

In his State of the Union, Biden takes clear aim at 'Big Pharma'

This gene therapy has record $4.25 million price. It's saved children.

Bring on the sabbaticals for nurses

Erich Jarvis studies song birds to learn about human stuttering

Air quality improving but still lags in Black, Hispanic communities

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

hotspot

Wikipedia

entertainment

Psychedelics group wrestles with new pharma identity

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Tori Bowie and the unacceptable rates of Black maternal death

Change Healthcare cyberattack prompts Medicare loan program

Moonlake's readout produced a cash windfall. Risks remain

Texas board proposes rules on abortion law emergency exemption

What does generative AI mean for health care? We asked experts

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

knowledge

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

How to bring more disabled researchers into academia

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Amylyx ALS drug fails large clinical trial

Bring on the sabbaticals for nurses

Amylyx ALS drug failure raises questions and concerns

explore

focus

focus

leisure time